Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical reported a 10.8% revenue growth in Q3 2022, reaching $27.8 million, compared to $25.1 million in Q2 2022. Gross margin improved to 15.6% from 11.2% in Q3 2021. Full-year revenue guidance is now set between $111 million and $113 million, up from previous guidance of $105 million to $110 million. Key achievements include resuming shipments to home patients and a five-year contract with the Department of Veterans Affairs.
Outset Medical, Inc. (Nasdaq: OM) has secured $300 million in senior secured credit facilities from SLR Capital Partners, including a $250 million term loan and a $50 million revolving credit facility. The term loan includes a $200 million commitment, extendable to $250 million, with interest-only payments for up to 54 months. Outset has drawn $100 million at closing. The financing aims to enhance the company's balance sheet and support its dialysis technology advancements. Maturity is set for November 1, 2027.
Outset Medical announces eight new abstracts highlighting home dialysis innovations at the American Society of Nephrology's Kidney Week 2022. Research indicates that patients using the Tablo Hemodialysis System experience lower attrition rates compared to other modalities, demonstrating high treatment adherence with 100% patient retention. Key findings emphasize that both patients and clinicians can effectively use the technology. Abstracts also showcase improved efficiency, cost reduction, and successful home dialysis program implementation, reflecting Outset's commitment to enhancing kidney care.
Outset Medical, Inc. (OM) will release its third-quarter financial results on November 8, 2022, after market close. A conference call is scheduled for 2:00 PM PT on the same day, featuring CEO Leslie Trigg and CFO Nabeel Ahmed. Interested parties can register online to receive dial-in information. Outset is known for its innovative Tablo® Hemodialysis System, designed to make dialysis more accessible and efficient, supporting care from hospital to home. This technology integrates water purification and dialysate production, enhancing patient experience and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) announced participation in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 13, 2022, at 11:55am PT / 2:55pm ET. The event will be accessible through a live and archived webcast on the company’s website. Outset Medical is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis for providers and enhance patient experiences. This technology enables dialysis delivery in various settings with integrated water purification and data analytics capabilities.
Outset Medical, Inc. (NASDAQ: OM) has secured a national contract with the United States Department of Veterans Affairs to enhance the availability of its Tablo® Hemodialysis System in 106 VA hospitals across the U.S. This five-year contract allows for indefinite quantities of Tablo units to provide advanced dialysis care, benefiting 35,000 veterans. The Tablo system, FDA-cleared, supports at-home and acute care, featuring two-way cloud communication for patient monitoring, thus transforming the dialysis experience.
Outset Medical, Inc. (Nasdaq: OM) announces FDA clearance for the Tablo® Hemodialysis System and resumes shipments for home use, reflecting a commitment to patient autonomy in dialysis.
For Q2 2022, revenue reached $25.1 million, matching prior guidance, with gross margin improving to 15.1% compared to 4.2% in Q2 2021. However, operating expenses rose to $47.5 million, contributing to a net loss of ($43.8) million.
Full-year guidance projects revenue between $105 million and $110 million, indicating modest growth over 2021.
Outset Medical, Inc. (NASDAQ: OM) announced a shipment hold on its Tablo Hemodialysis System for home use, pending FDA review of a 510(k) submission for updates since its original March 2020 clearance. The company reports no safety issues with Tablo and will continue marketing it for healthcare professionals. Revised revenue expectations for the second quarter of 2022 are now at least $25 million. An update on the regulatory review is anticipated in Q3, with specifics on 2022 financial goals coming in early August.
Outset Medical, Inc. (Nasdaq: OM) has announced management participation in two investor conferences. The UBS Global Healthcare Conference will take place on May 24, 2022, at 4:45am PT, while the Goldman Sachs 43rd Annual Global Healthcare Conference is set for June 14, 2022, at 3:20pm PT. A live and archived webcast of these fireside chats will be available on Outset's investor website. Outset continues to innovate with its Tablo Hemodialysis System, designed to enhance dialysis care accessibility and efficiency.
Outset Medical, Inc. (Nasdaq: OM) announces a virtual webinar on the Tablo® Hemodialysis System for home dialysis, taking place on June 1, 2022, at 1:00 PM PT / 4:00 PM ET. The event features discussions between patients and nephrologists, moderated by Michael Aragon, MD. It aims to share patient experiences and the journey of home dialysis. Attendees can register here. An archived version will be available on Outset's website.